by freeoxbio-admin | Oct 7, 2020 | News
FreeOx Biotech has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use of Ox-01 until 2038 for patients with ischaemic stroke treated with mechanical thrombectomy. “This grant...
by freeoxbio-admin | Oct 29, 2019 | News
En motiu del Dia Mundial de l’Ictus, el programa La nit dels ignorants de Catalunya Ràdio ha entrevistat el Dr. Ángel Chamorro, un dels principals especialistes en l’ictus, director de la Unitat Funcional de Patologia Vascular Cerebral de l’Hospital...
by freeoxbio-admin | Oct 5, 2019 | News
Entrevista del Dr. Ángel Chamorro en Misderechos.club en la cual explica los síntomas, factores de riesgo e incidencia del ictus, una patología que afecta a 17 millones de personas en todo el mundo. El Dr. Chamorro es neurólogo, director de la Unidad Funcional de...
by freeoxbio-admin | Mar 15, 2019 | News
FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia. The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand...
by freeoxbio-admin | Nov 8, 2018 | News
FreeOx Biotech has closed its first round of funding with €500,000 from private investors Montserrat Esteve and Francisco Javier Alsina. Created as a spin-out of Hospital Clinic Barcelona–IDIBAPS in 2017 to develop a new class of neuroprotective drugs, FreeOx...
